nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—hypertension—type 2 diabetes mellitus	0.429	1	CtDrD
Nadolol—ADRB3—type 2 diabetes mellitus	0.29	1	CbGaD
Nadolol—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.0487	0.312	CbGbCtD
Nadolol—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0298	0.191	CbGbCtD
Nadolol—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0265	0.17	CbGbCtD
Nadolol—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0192	0.123	CbGbCtD
Nadolol—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0132	0.0844	CbGbCtD
Nadolol—ABCB1—Glyburide—type 2 diabetes mellitus	0.00982	0.0629	CbGbCtD
Nadolol—ABCB1—Losartan—type 2 diabetes mellitus	0.00898	0.0575	CbGbCtD
Nadolol—ADRB3—brown adipose tissue—type 2 diabetes mellitus	0.00525	0.693	CbGeAlD
Nadolol—Bupranolol—ADRB3—type 2 diabetes mellitus	0.000743	0.539	CrCbGaD
Nadolol—ADRB3—adipose tissue—type 2 diabetes mellitus	0.000708	0.0935	CbGeAlD
Nadolol—Pindolol—ADRB3—type 2 diabetes mellitus	0.00049	0.355	CrCbGaD
Nadolol—ADRB1—cardiovascular system—type 2 diabetes mellitus	0.000328	0.0434	CbGeAlD
Nadolol—ADRB1—adipose tissue—type 2 diabetes mellitus	0.000289	0.0382	CbGeAlD
Nadolol—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000152	0.0201	CbGeAlD
Nadolol—Salbutamol—CYP3A4—type 2 diabetes mellitus	0.000145	0.106	CrCbGaD
Nadolol—ABCB1—retina—type 2 diabetes mellitus	0.00013	0.0172	CbGeAlD
Nadolol—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000122	0.0162	CbGeAlD
Nadolol—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.00011	0.0145	CbGeAlD
Nadolol—ABCB1—kidney—type 2 diabetes mellitus	0.000108	0.0142	CbGeAlD
Nadolol—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000108	0.00132	CcSEcCtD
Nadolol—Agranulocytosis—Losartan—type 2 diabetes mellitus	0.000107	0.00131	CcSEcCtD
Nadolol—ABCB1—pancreas—type 2 diabetes mellitus	0.000107	0.0141	CbGeAlD
Nadolol—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000107	0.00131	CcSEcCtD
Nadolol—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.000106	0.0013	CcSEcCtD
Nadolol—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000106	0.0013	CcSEcCtD
Nadolol—Abdominal discomfort—Ramipril—type 2 diabetes mellitus	0.000106	0.0013	CcSEcCtD
Nadolol—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000106	0.0013	CcSEcCtD
Nadolol—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000105	0.00129	CcSEcCtD
Nadolol—Cough—Gliclazide—type 2 diabetes mellitus	0.000105	0.00129	CcSEcCtD
Nadolol—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000105	0.0138	CbGeAlD
Nadolol—Anorexia—Glyburide—type 2 diabetes mellitus	0.000104	0.00128	CcSEcCtD
Nadolol—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000104	0.00128	CcSEcCtD
Nadolol—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000104	0.00128	CcSEcCtD
Nadolol—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000104	0.00128	CcSEcCtD
Nadolol—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000103	0.00127	CcSEcCtD
Nadolol—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000103	0.00127	CcSEcCtD
Nadolol—Chest pain—Gliclazide—type 2 diabetes mellitus	0.000103	0.00126	CcSEcCtD
Nadolol—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000103	0.00126	CcSEcCtD
Nadolol—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000103	0.00126	CcSEcCtD
Nadolol—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000102	0.00126	CcSEcCtD
Nadolol—Hypotension—Glyburide—type 2 diabetes mellitus	0.000102	0.00126	CcSEcCtD
Nadolol—Nausea—Repaglinide—type 2 diabetes mellitus	0.000102	0.00126	CcSEcCtD
Nadolol—Asthenia—Glipizide—type 2 diabetes mellitus	0.000102	0.00125	CcSEcCtD
Nadolol—Tinnitus—Irbesartan—type 2 diabetes mellitus	0.000102	0.00125	CcSEcCtD
Nadolol—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.000102	0.00125	CcSEcCtD
Nadolol—Pruritus—Glipizide—type 2 diabetes mellitus	0.000101	0.00124	CcSEcCtD
Nadolol—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.0001	0.00123	CcSEcCtD
Nadolol—Weight increased—Ramipril—type 2 diabetes mellitus	0.0001	0.00123	CcSEcCtD
Nadolol—Flatulence—Metformin—type 2 diabetes mellitus	9.94e-05	0.00122	CcSEcCtD
Nadolol—Syncope—Valsartan—type 2 diabetes mellitus	9.93e-05	0.00122	CcSEcCtD
Nadolol—Paraesthesia—Glyburide—type 2 diabetes mellitus	9.84e-05	0.00121	CcSEcCtD
Nadolol—Asthenia—Pioglitazone—type 2 diabetes mellitus	9.79e-05	0.0012	CcSEcCtD
Nadolol—Dyspnoea—Glyburide—type 2 diabetes mellitus	9.77e-05	0.0012	CcSEcCtD
Nadolol—Diarrhoea—Glipizide—type 2 diabetes mellitus	9.74e-05	0.0012	CcSEcCtD
Nadolol—Loss of consciousness—Valsartan—type 2 diabetes mellitus	9.74e-05	0.0012	CcSEcCtD
Nadolol—ABCB1—adipose tissue—type 2 diabetes mellitus	9.7e-05	0.0128	CbGeAlD
Nadolol—Cough—Valsartan—type 2 diabetes mellitus	9.67e-05	0.00119	CcSEcCtD
Nadolol—Nausea—Rosiglitazone—type 2 diabetes mellitus	9.66e-05	0.00119	CcSEcCtD
Nadolol—Dyspepsia—Glyburide—type 2 diabetes mellitus	9.65e-05	0.00118	CcSEcCtD
Nadolol—Tinnitus—Losartan—type 2 diabetes mellitus	9.6e-05	0.00118	CcSEcCtD
Nadolol—Conjunctivitis—Ramipril—type 2 diabetes mellitus	9.56e-05	0.00117	CcSEcCtD
Nadolol—Cough—Orlistat—type 2 diabetes mellitus	9.55e-05	0.00117	CcSEcCtD
Nadolol—Asthenia—Glimepiride—type 2 diabetes mellitus	9.53e-05	0.00117	CcSEcCtD
Nadolol—Decreased appetite—Glyburide—type 2 diabetes mellitus	9.53e-05	0.00117	CcSEcCtD
Nadolol—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	9.51e-05	0.00117	CcSEcCtD
Nadolol—Vision blurred—Metformin—type 2 diabetes mellitus	9.51e-05	0.00117	CcSEcCtD
Nadolol—Asthenia—Sitagliptin—type 2 diabetes mellitus	9.5e-05	0.00117	CcSEcCtD
Nadolol—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	9.48e-05	0.00116	CcSEcCtD
Nadolol—Chest pain—Valsartan—type 2 diabetes mellitus	9.43e-05	0.00116	CcSEcCtD
Nadolol—Sweating—Ramipril—type 2 diabetes mellitus	9.42e-05	0.00116	CcSEcCtD
Nadolol—Dizziness—Glipizide—type 2 diabetes mellitus	9.42e-05	0.00116	CcSEcCtD
Nadolol—Pruritus—Glimepiride—type 2 diabetes mellitus	9.4e-05	0.00115	CcSEcCtD
Nadolol—Flatulence—Irbesartan—type 2 diabetes mellitus	9.38e-05	0.00115	CcSEcCtD
Nadolol—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	9.33e-05	0.00115	CcSEcCtD
Nadolol—Chest pain—Orlistat—type 2 diabetes mellitus	9.32e-05	0.00114	CcSEcCtD
Nadolol—Dry mouth—Valsartan—type 2 diabetes mellitus	9.22e-05	0.00113	CcSEcCtD
Nadolol—Hypotension—Gliclazide—type 2 diabetes mellitus	9.2e-05	0.00113	CcSEcCtD
Nadolol—Agranulocytosis—Ramipril—type 2 diabetes mellitus	9.17e-05	0.00113	CcSEcCtD
Nadolol—Dry mouth—Orlistat—type 2 diabetes mellitus	9.11e-05	0.00112	CcSEcCtD
Nadolol—Alopecia—Losartan—type 2 diabetes mellitus	9.09e-05	0.00112	CcSEcCtD
Nadolol—Diarrhoea—Glimepiride—type 2 diabetes mellitus	9.09e-05	0.00112	CcSEcCtD
Nadolol—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	9.06e-05	0.00111	CcSEcCtD
Nadolol—Vomiting—Glipizide—type 2 diabetes mellitus	9.05e-05	0.00111	CcSEcCtD
Nadolol—Syncope—Metformin—type 2 diabetes mellitus	9.05e-05	0.00111	CcSEcCtD
Nadolol—Oedema—Valsartan—type 2 diabetes mellitus	9.04e-05	0.00111	CcSEcCtD
Nadolol—Dizziness—Pioglitazone—type 2 diabetes mellitus	9.02e-05	0.00111	CcSEcCtD
Nadolol—Rash—Glipizide—type 2 diabetes mellitus	8.98e-05	0.0011	CcSEcCtD
Nadolol—Vision blurred—Irbesartan—type 2 diabetes mellitus	8.97e-05	0.0011	CcSEcCtD
Nadolol—Dermatitis—Glipizide—type 2 diabetes mellitus	8.97e-05	0.0011	CcSEcCtD
Nadolol—Oedema—Orlistat—type 2 diabetes mellitus	8.93e-05	0.0011	CcSEcCtD
Nadolol—Insomnia—Gliclazide—type 2 diabetes mellitus	8.9e-05	0.00109	CcSEcCtD
Nadolol—Shock—Valsartan—type 2 diabetes mellitus	8.9e-05	0.00109	CcSEcCtD
Nadolol—Loss of consciousness—Metformin—type 2 diabetes mellitus	8.87e-05	0.00109	CcSEcCtD
Nadolol—Paraesthesia—Gliclazide—type 2 diabetes mellitus	8.84e-05	0.00109	CcSEcCtD
Nadolol—Flatulence—Losartan—type 2 diabetes mellitus	8.83e-05	0.00108	CcSEcCtD
Nadolol—Dizziness—Glimepiride—type 2 diabetes mellitus	8.79e-05	0.00108	CcSEcCtD
Nadolol—Dyspnoea—Gliclazide—type 2 diabetes mellitus	8.77e-05	0.00108	CcSEcCtD
Nadolol—Dizziness—Sitagliptin—type 2 diabetes mellitus	8.76e-05	0.00108	CcSEcCtD
Nadolol—Hypertension—Metformin—type 2 diabetes mellitus	8.71e-05	0.00107	CcSEcCtD
Nadolol—Dyspepsia—Gliclazide—type 2 diabetes mellitus	8.66e-05	0.00106	CcSEcCtD
Nadolol—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	8.64e-05	0.00106	CcSEcCtD
Nadolol—Anorexia—Valsartan—type 2 diabetes mellitus	8.62e-05	0.00106	CcSEcCtD
Nadolol—Asthenia—Bromocriptine—type 2 diabetes mellitus	8.6e-05	0.00106	CcSEcCtD
Nadolol—Chest pain—Metformin—type 2 diabetes mellitus	8.59e-05	0.00105	CcSEcCtD
Nadolol—Syncope—Irbesartan—type 2 diabetes mellitus	8.54e-05	0.00105	CcSEcCtD
Nadolol—Visual impairment—Ramipril—type 2 diabetes mellitus	8.5e-05	0.00104	CcSEcCtD
Nadolol—Fatigue—Gliclazide—type 2 diabetes mellitus	8.48e-05	0.00104	CcSEcCtD
Nadolol—Nausea—Glipizide—type 2 diabetes mellitus	8.46e-05	0.00104	CcSEcCtD
Nadolol—Vomiting—Glimepiride—type 2 diabetes mellitus	8.45e-05	0.00104	CcSEcCtD
Nadolol—Hypotension—Valsartan—type 2 diabetes mellitus	8.45e-05	0.00104	CcSEcCtD
Nadolol—Vision blurred—Losartan—type 2 diabetes mellitus	8.44e-05	0.00104	CcSEcCtD
Nadolol—Vomiting—Sitagliptin—type 2 diabetes mellitus	8.42e-05	0.00103	CcSEcCtD
Nadolol—Pain—Gliclazide—type 2 diabetes mellitus	8.42e-05	0.00103	CcSEcCtD
Nadolol—Constipation—Gliclazide—type 2 diabetes mellitus	8.42e-05	0.00103	CcSEcCtD
Nadolol—Rash—Glimepiride—type 2 diabetes mellitus	8.38e-05	0.00103	CcSEcCtD
Nadolol—Dermatitis—Glimepiride—type 2 diabetes mellitus	8.37e-05	0.00103	CcSEcCtD
Nadolol—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	8.37e-05	0.00103	CcSEcCtD
Nadolol—Rash—Sitagliptin—type 2 diabetes mellitus	8.35e-05	0.00103	CcSEcCtD
Nadolol—Dermatitis—Sitagliptin—type 2 diabetes mellitus	8.34e-05	0.00102	CcSEcCtD
Nadolol—Cough—Irbesartan—type 2 diabetes mellitus	8.31e-05	0.00102	CcSEcCtD
Nadolol—Oedema—Metformin—type 2 diabetes mellitus	8.23e-05	0.00101	CcSEcCtD
Nadolol—Tinnitus—Ramipril—type 2 diabetes mellitus	8.23e-05	0.00101	CcSEcCtD
Nadolol—Hypertension—Irbesartan—type 2 diabetes mellitus	8.22e-05	0.00101	CcSEcCtD
Nadolol—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	8.2e-05	0.00101	CcSEcCtD
Nadolol—Insomnia—Valsartan—type 2 diabetes mellitus	8.18e-05	0.001	CcSEcCtD
Nadolol—Paraesthesia—Valsartan—type 2 diabetes mellitus	8.12e-05	0.000997	CcSEcCtD
Nadolol—Chest pain—Irbesartan—type 2 diabetes mellitus	8.11e-05	0.000995	CcSEcCtD
Nadolol—Shock—Metformin—type 2 diabetes mellitus	8.1e-05	0.000995	CcSEcCtD
Nadolol—Insomnia—Orlistat—type 2 diabetes mellitus	8.08e-05	0.000992	CcSEcCtD
Nadolol—Dyspnoea—Valsartan—type 2 diabetes mellitus	8.06e-05	0.00099	CcSEcCtD
Nadolol—Syncope—Losartan—type 2 diabetes mellitus	8.03e-05	0.000987	CcSEcCtD
Nadolol—Paraesthesia—Orlistat—type 2 diabetes mellitus	8.02e-05	0.000985	CcSEcCtD
Nadolol—Hyperhidrosis—Metformin—type 2 diabetes mellitus	7.96e-05	0.000977	CcSEcCtD
Nadolol—Dyspepsia—Valsartan—type 2 diabetes mellitus	7.96e-05	0.000977	CcSEcCtD
Nadolol—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.93e-05	0.000974	CcSEcCtD
Nadolol—Dry mouth—Irbesartan—type 2 diabetes mellitus	7.93e-05	0.000973	CcSEcCtD
Nadolol—Nausea—Glimepiride—type 2 diabetes mellitus	7.89e-05	0.000969	CcSEcCtD
Nadolol—Loss of consciousness—Losartan—type 2 diabetes mellitus	7.87e-05	0.000967	CcSEcCtD
Nadolol—Nausea—Sitagliptin—type 2 diabetes mellitus	7.87e-05	0.000966	CcSEcCtD
Nadolol—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.86e-05	0.000966	CcSEcCtD
Nadolol—Asthenia—Glyburide—type 2 diabetes mellitus	7.86e-05	0.000966	CcSEcCtD
Nadolol—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.86e-05	0.000965	CcSEcCtD
Nadolol—Anorexia—Metformin—type 2 diabetes mellitus	7.85e-05	0.000964	CcSEcCtD
Nadolol—Cough—Losartan—type 2 diabetes mellitus	7.82e-05	0.00096	CcSEcCtD
Nadolol—Alopecia—Ramipril—type 2 diabetes mellitus	7.8e-05	0.000958	CcSEcCtD
Nadolol—Fatigue—Valsartan—type 2 diabetes mellitus	7.8e-05	0.000957	CcSEcCtD
Nadolol—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.78e-05	0.000955	CcSEcCtD
Nadolol—Oedema—Irbesartan—type 2 diabetes mellitus	7.77e-05	0.000954	CcSEcCtD
Nadolol—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.77e-05	0.000954	CcSEcCtD
Nadolol—Pruritus—Glyburide—type 2 diabetes mellitus	7.75e-05	0.000952	CcSEcCtD
Nadolol—Constipation—Valsartan—type 2 diabetes mellitus	7.73e-05	0.000949	CcSEcCtD
Nadolol—Fatigue—Orlistat—type 2 diabetes mellitus	7.7e-05	0.000946	CcSEcCtD
Nadolol—Hypotension—Metformin—type 2 diabetes mellitus	7.69e-05	0.000945	CcSEcCtD
Nadolol—Shock—Irbesartan—type 2 diabetes mellitus	7.64e-05	0.000939	CcSEcCtD
Nadolol—Pain—Orlistat—type 2 diabetes mellitus	7.64e-05	0.000938	CcSEcCtD
Nadolol—Chest pain—Losartan—type 2 diabetes mellitus	7.63e-05	0.000937	CcSEcCtD
Nadolol—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.62e-05	0.000936	CcSEcCtD
Nadolol—Rash—Bromocriptine—type 2 diabetes mellitus	7.56e-05	0.000928	CcSEcCtD
Nadolol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.55e-05	0.000927	CcSEcCtD
Nadolol—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.51e-05	0.000922	CcSEcCtD
Nadolol—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.5e-05	0.000921	CcSEcCtD
Nadolol—Dry mouth—Losartan—type 2 diabetes mellitus	7.46e-05	0.000916	CcSEcCtD
Nadolol—Anorexia—Irbesartan—type 2 diabetes mellitus	7.41e-05	0.00091	CcSEcCtD
Nadolol—Paraesthesia—Metformin—type 2 diabetes mellitus	7.39e-05	0.000908	CcSEcCtD
Nadolol—Dyspnoea—Metformin—type 2 diabetes mellitus	7.34e-05	0.000901	CcSEcCtD
Nadolol—Oedema—Losartan—type 2 diabetes mellitus	7.31e-05	0.000898	CcSEcCtD
Nadolol—Hypotension—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.000892	CcSEcCtD
Nadolol—Dyspepsia—Metformin—type 2 diabetes mellitus	7.25e-05	0.00089	CcSEcCtD
Nadolol—Shock—Losartan—type 2 diabetes mellitus	7.19e-05	0.000883	CcSEcCtD
Nadolol—Decreased appetite—Metformin—type 2 diabetes mellitus	7.16e-05	0.000879	CcSEcCtD
Nadolol—Nausea—Bromocriptine—type 2 diabetes mellitus	7.12e-05	0.000874	CcSEcCtD
Nadolol—Fatigue—Metformin—type 2 diabetes mellitus	7.1e-05	0.000872	CcSEcCtD
Nadolol—Hyperhidrosis—Losartan—type 2 diabetes mellitus	7.07e-05	0.000868	CcSEcCtD
Nadolol—Body temperature increased—Orlistat—type 2 diabetes mellitus	7.06e-05	0.000867	CcSEcCtD
Nadolol—Asthenia—Gliclazide—type 2 diabetes mellitus	7.06e-05	0.000867	CcSEcCtD
Nadolol—Constipation—Metformin—type 2 diabetes mellitus	7.04e-05	0.000865	CcSEcCtD
Nadolol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.98e-05	0.000857	CcSEcCtD
Nadolol—Anorexia—Losartan—type 2 diabetes mellitus	6.97e-05	0.000856	CcSEcCtD
Nadolol—Vomiting—Glyburide—type 2 diabetes mellitus	6.97e-05	0.000856	CcSEcCtD
Nadolol—Pruritus—Gliclazide—type 2 diabetes mellitus	6.96e-05	0.000855	CcSEcCtD
Nadolol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.93e-05	0.000851	CcSEcCtD
Nadolol—Rash—Glyburide—type 2 diabetes mellitus	6.91e-05	0.000849	CcSEcCtD
Nadolol—Dermatitis—Glyburide—type 2 diabetes mellitus	6.9e-05	0.000848	CcSEcCtD
Nadolol—Syncope—Ramipril—type 2 diabetes mellitus	6.89e-05	0.000846	CcSEcCtD
Nadolol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.84e-05	0.00084	CcSEcCtD
Nadolol—Hypotension—Losartan—type 2 diabetes mellitus	6.83e-05	0.000839	CcSEcCtD
Nadolol—ABCB1—liver—type 2 diabetes mellitus	6.8e-05	0.00898	CbGeAlD
Nadolol—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.75e-05	0.000829	CcSEcCtD
Nadolol—Loss of consciousness—Ramipril—type 2 diabetes mellitus	6.75e-05	0.000829	CcSEcCtD
Nadolol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.73e-05	0.000827	CcSEcCtD
Nadolol—Cough—Ramipril—type 2 diabetes mellitus	6.7e-05	0.000823	CcSEcCtD
Nadolol—Fatigue—Irbesartan—type 2 diabetes mellitus	6.7e-05	0.000823	CcSEcCtD
Nadolol—Pain—Irbesartan—type 2 diabetes mellitus	6.64e-05	0.000816	CcSEcCtD
Nadolol—Constipation—Irbesartan—type 2 diabetes mellitus	6.64e-05	0.000816	CcSEcCtD
Nadolol—Insomnia—Losartan—type 2 diabetes mellitus	6.61e-05	0.000812	CcSEcCtD
Nadolol—Paraesthesia—Losartan—type 2 diabetes mellitus	6.57e-05	0.000806	CcSEcCtD
Nadolol—Chest pain—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000803	CcSEcCtD
Nadolol—Dyspnoea—Losartan—type 2 diabetes mellitus	6.52e-05	0.000801	CcSEcCtD
Nadolol—Nausea—Glyburide—type 2 diabetes mellitus	6.51e-05	0.000799	CcSEcCtD
Nadolol—Dizziness—Gliclazide—type 2 diabetes mellitus	6.51e-05	0.000799	CcSEcCtD
Nadolol—Asthenia—Valsartan—type 2 diabetes mellitus	6.49e-05	0.000797	CcSEcCtD
Nadolol—Dyspepsia—Losartan—type 2 diabetes mellitus	6.44e-05	0.00079	CcSEcCtD
Nadolol—Asthenia—Orlistat—type 2 diabetes mellitus	6.41e-05	0.000787	CcSEcCtD
Nadolol—Pruritus—Valsartan—type 2 diabetes mellitus	6.4e-05	0.000786	CcSEcCtD
Nadolol—Dry mouth—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000786	CcSEcCtD
Nadolol—Decreased appetite—Losartan—type 2 diabetes mellitus	6.36e-05	0.000781	CcSEcCtD
Nadolol—Pruritus—Orlistat—type 2 diabetes mellitus	6.32e-05	0.000776	CcSEcCtD
Nadolol—Fatigue—Losartan—type 2 diabetes mellitus	6.3e-05	0.000774	CcSEcCtD
Nadolol—Oedema—Ramipril—type 2 diabetes mellitus	6.27e-05	0.00077	CcSEcCtD
Nadolol—Vomiting—Gliclazide—type 2 diabetes mellitus	6.26e-05	0.000768	CcSEcCtD
Nadolol—Constipation—Losartan—type 2 diabetes mellitus	6.25e-05	0.000768	CcSEcCtD
Nadolol—Pain—Losartan—type 2 diabetes mellitus	6.25e-05	0.000768	CcSEcCtD
Nadolol—Rash—Gliclazide—type 2 diabetes mellitus	6.2e-05	0.000762	CcSEcCtD
Nadolol—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.2e-05	0.000761	CcSEcCtD
Nadolol—Diarrhoea—Valsartan—type 2 diabetes mellitus	6.19e-05	0.00076	CcSEcCtD
Nadolol—Shock—Ramipril—type 2 diabetes mellitus	6.17e-05	0.000758	CcSEcCtD
Nadolol—Body temperature increased—Irbesartan—type 2 diabetes mellitus	6.14e-05	0.000754	CcSEcCtD
Nadolol—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.11e-05	0.000751	CcSEcCtD
Nadolol—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000744	CcSEcCtD
Nadolol—Dizziness—Valsartan—type 2 diabetes mellitus	5.98e-05	0.000734	CcSEcCtD
Nadolol—Anorexia—Ramipril—type 2 diabetes mellitus	5.98e-05	0.000734	CcSEcCtD
Nadolol—Dizziness—Orlistat—type 2 diabetes mellitus	5.91e-05	0.000726	CcSEcCtD
Nadolol—Asthenia—Metformin—type 2 diabetes mellitus	5.91e-05	0.000725	CcSEcCtD
Nadolol—Hypotension—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000719	CcSEcCtD
Nadolol—Nausea—Gliclazide—type 2 diabetes mellitus	5.85e-05	0.000718	CcSEcCtD
Nadolol—Pruritus—Metformin—type 2 diabetes mellitus	5.83e-05	0.000715	CcSEcCtD
Nadolol—Body temperature increased—Losartan—type 2 diabetes mellitus	5.78e-05	0.00071	CcSEcCtD
Nadolol—Vomiting—Valsartan—type 2 diabetes mellitus	5.75e-05	0.000706	CcSEcCtD
Nadolol—Rash—Valsartan—type 2 diabetes mellitus	5.7e-05	0.0007	CcSEcCtD
Nadolol—Dermatitis—Valsartan—type 2 diabetes mellitus	5.7e-05	0.000699	CcSEcCtD
Nadolol—Vomiting—Orlistat—type 2 diabetes mellitus	5.68e-05	0.000698	CcSEcCtD
Nadolol—Insomnia—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000696	CcSEcCtD
Nadolol—Diarrhoea—Metformin—type 2 diabetes mellitus	5.63e-05	0.000692	CcSEcCtD
Nadolol—Rash—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000692	CcSEcCtD
Nadolol—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000691	CcSEcCtD
Nadolol—Dermatitis—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000691	CcSEcCtD
Nadolol—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000686	CcSEcCtD
Nadolol—Asthenia—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.000685	CcSEcCtD
Nadolol—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.52e-05	0.000678	CcSEcCtD
Nadolol—Pruritus—Irbesartan—type 2 diabetes mellitus	5.5e-05	0.000675	CcSEcCtD
Nadolol—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.45e-05	0.000669	CcSEcCtD
Nadolol—Dizziness—Metformin—type 2 diabetes mellitus	5.44e-05	0.000669	CcSEcCtD
Nadolol—Fatigue—Ramipril—type 2 diabetes mellitus	5.41e-05	0.000664	CcSEcCtD
Nadolol—Nausea—Valsartan—type 2 diabetes mellitus	5.37e-05	0.00066	CcSEcCtD
Nadolol—Constipation—Ramipril—type 2 diabetes mellitus	5.36e-05	0.000658	CcSEcCtD
Nadolol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.32e-05	0.000653	CcSEcCtD
Nadolol—Nausea—Orlistat—type 2 diabetes mellitus	5.31e-05	0.000652	CcSEcCtD
Nadolol—Asthenia—Losartan—type 2 diabetes mellitus	5.25e-05	0.000644	CcSEcCtD
Nadolol—Vomiting—Metformin—type 2 diabetes mellitus	5.23e-05	0.000643	CcSEcCtD
Nadolol—Rash—Metformin—type 2 diabetes mellitus	5.19e-05	0.000638	CcSEcCtD
Nadolol—Dermatitis—Metformin—type 2 diabetes mellitus	5.19e-05	0.000637	CcSEcCtD
Nadolol—Pruritus—Losartan—type 2 diabetes mellitus	5.17e-05	0.000635	CcSEcCtD
Nadolol—Dizziness—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000631	CcSEcCtD
Nadolol—Diarrhoea—Losartan—type 2 diabetes mellitus	5e-05	0.000614	CcSEcCtD
Nadolol—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.96e-05	0.000609	CcSEcCtD
Nadolol—Vomiting—Irbesartan—type 2 diabetes mellitus	4.94e-05	0.000607	CcSEcCtD
Nadolol—Rash—Irbesartan—type 2 diabetes mellitus	4.9e-05	0.000602	CcSEcCtD
Nadolol—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.89e-05	0.000601	CcSEcCtD
Nadolol—Nausea—Metformin—type 2 diabetes mellitus	4.89e-05	0.000601	CcSEcCtD
Nadolol—Dizziness—Losartan—type 2 diabetes mellitus	4.84e-05	0.000594	CcSEcCtD
Nadolol—Vomiting—Losartan—type 2 diabetes mellitus	4.65e-05	0.000571	CcSEcCtD
Nadolol—Nausea—Irbesartan—type 2 diabetes mellitus	4.62e-05	0.000567	CcSEcCtD
Nadolol—Rash—Losartan—type 2 diabetes mellitus	4.61e-05	0.000566	CcSEcCtD
Nadolol—Dermatitis—Losartan—type 2 diabetes mellitus	4.61e-05	0.000566	CcSEcCtD
Nadolol—Asthenia—Ramipril—type 2 diabetes mellitus	4.5e-05	0.000552	CcSEcCtD
Nadolol—Pruritus—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000545	CcSEcCtD
Nadolol—Nausea—Losartan—type 2 diabetes mellitus	4.34e-05	0.000533	CcSEcCtD
Nadolol—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.29e-05	0.000527	CcSEcCtD
Nadolol—Dizziness—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000509	CcSEcCtD
Nadolol—Vomiting—Ramipril—type 2 diabetes mellitus	3.99e-05	0.00049	CcSEcCtD
Nadolol—Rash—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000485	CcSEcCtD
Nadolol—Dermatitis—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000485	CcSEcCtD
Nadolol—Nausea—Ramipril—type 2 diabetes mellitus	3.72e-05	0.000457	CcSEcCtD
Nadolol—ADRB1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	8.25e-06	0.000237	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.25e-06	0.000237	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC5A2—type 2 diabetes mellitus	8.15e-06	0.000234	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—COX2—type 2 diabetes mellitus	8.15e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	8.14e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	8.14e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	8.12e-06	0.000233	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	8.11e-06	0.000233	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—type 2 diabetes mellitus	8.11e-06	0.000233	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.1e-06	0.000233	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	8.07e-06	0.000232	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA6—type 2 diabetes mellitus	8.01e-06	0.00023	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	7.96e-06	0.000229	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—C3—type 2 diabetes mellitus	7.96e-06	0.000229	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—C3—type 2 diabetes mellitus	7.92e-06	0.000228	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	7.9e-06	0.000227	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—type 2 diabetes mellitus	7.89e-06	0.000227	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HSD11B1—type 2 diabetes mellitus	7.87e-06	0.000226	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—UCP2—type 2 diabetes mellitus	7.87e-06	0.000226	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—UCP3—type 2 diabetes mellitus	7.87e-06	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—C3—type 2 diabetes mellitus	7.78e-06	0.000224	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	7.73e-06	0.000222	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	7.69e-06	0.000221	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	7.67e-06	0.00022	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	7.67e-06	0.00022	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	7.61e-06	0.000219	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	7.58e-06	0.000218	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.56e-06	0.000217	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.55e-06	0.000217	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.53e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	7.52e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGT—type 2 diabetes mellitus	7.52e-06	0.000216	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	7.51e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	7.5e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	7.5e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.46e-06	0.000214	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.43e-06	0.000214	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.43e-06	0.000214	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PCK1—type 2 diabetes mellitus	7.4e-06	0.000213	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.4e-06	0.000213	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.39e-06	0.000213	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOE—type 2 diabetes mellitus	7.37e-06	0.000212	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LEP—type 2 diabetes mellitus	7.37e-06	0.000212	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	7.3e-06	0.00021	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.3e-06	0.00021	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.29e-06	0.000209	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLAT—type 2 diabetes mellitus	7.27e-06	0.000209	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GHRL—type 2 diabetes mellitus	7.27e-06	0.000209	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.27e-06	0.000209	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.27e-06	0.000209	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	7.26e-06	0.000209	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—type 2 diabetes mellitus	7.25e-06	0.000208	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.18e-06	0.000206	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	7.14e-06	0.000205	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLAT—type 2 diabetes mellitus	7.11e-06	0.000204	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GHRL—type 2 diabetes mellitus	7.11e-06	0.000204	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 2 diabetes mellitus	7.1e-06	0.000204	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.03e-06	0.000202	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.98e-06	0.000201	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.95e-06	0.0002	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HK1—type 2 diabetes mellitus	6.93e-06	0.000199	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.83e-06	0.000196	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	6.78e-06	0.000195	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	6.77e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.77e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.73e-06	0.000194	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	6.69e-06	0.000192	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	6.69e-06	0.000192	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	6.69e-06	0.000192	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	6.69e-06	0.000192	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GCG—type 2 diabetes mellitus	6.65e-06	0.000191	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.65e-06	0.000191	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.62e-06	0.00019	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.59e-06	0.000189	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.58e-06	0.000189	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.54e-06	0.000188	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.52e-06	0.000187	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.51e-06	0.000187	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GCG—type 2 diabetes mellitus	6.51e-06	0.000187	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	6.42e-06	0.000184	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.4e-06	0.000184	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.38e-06	0.000183	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INS—type 2 diabetes mellitus	6.3e-06	0.000181	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.23e-06	0.000179	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.2e-06	0.000178	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	6.12e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.12e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.11e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.09e-06	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.09e-06	0.000175	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.09e-06	0.000175	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.06e-06	0.000174	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.98e-06	0.000172	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.98e-06	0.000172	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	5.97e-06	0.000171	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.79e-06	0.000166	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.78e-06	0.000166	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	5.74e-06	0.000165	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.73e-06	0.000165	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.66e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AVP—type 2 diabetes mellitus	5.66e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.66e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.63e-06	0.000162	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.61e-06	0.000161	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.61e-06	0.000161	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	5.57e-06	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.55e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AVP—type 2 diabetes mellitus	5.53e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.53e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.52e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.52e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.51e-06	0.000158	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.48e-06	0.000158	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOB—type 2 diabetes mellitus	5.47e-06	0.000157	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	5.46e-06	0.000157	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	5.46e-06	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.44e-06	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.43e-06	0.000156	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.38e-06	0.000155	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	5.35e-06	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOB—type 2 diabetes mellitus	5.35e-06	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.33e-06	0.000153	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	5.32e-06	0.000153	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	5.32e-06	0.000153	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	5.32e-06	0.000153	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	5.29e-06	0.000152	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.26e-06	0.000151	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LPL—type 2 diabetes mellitus	5.22e-06	0.00015	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RELA—type 2 diabetes mellitus	5.2e-06	0.000149	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	5.19e-06	0.000149	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	5.13e-06	0.000147	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.11e-06	0.000147	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LPL—type 2 diabetes mellitus	5.11e-06	0.000147	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	5.04e-06	0.000145	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5e-06	0.000144	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.9e-06	0.000141	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.81e-06	0.000138	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.79e-06	0.000138	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	4.77e-06	0.000137	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	4.77e-06	0.000137	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	4.77e-06	0.000137	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.73e-06	0.000136	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.7e-06	0.000135	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—C3—type 2 diabetes mellitus	4.7e-06	0.000135	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.69e-06	0.000135	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	4.68e-06	0.000135	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.66e-06	0.000134	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	4.64e-06	0.000133	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	4.6e-06	0.000132	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.55e-06	0.000131	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	4.54e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.48e-06	0.000129	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.47e-06	0.000128	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.47e-06	0.000128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.43e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.39e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.38e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.38e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.38e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.38e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.37e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	4.37e-06	0.000126	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	4.36e-06	0.000125	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.33e-06	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	4.31e-06	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	4.31e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.3e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.3e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	4.28e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	4.28e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.23e-06	0.000122	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	4.21e-06	0.000121	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	4.14e-06	0.000119	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	4.14e-06	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.13e-06	0.000119	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SRC—type 2 diabetes mellitus	4.09e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.04e-06	0.000116	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.98e-06	0.000114	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.9e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.82e-06	0.00011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INS—type 2 diabetes mellitus	3.74e-06	0.000107	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.68e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	3.66e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.65e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.62e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.61e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.6e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.6e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.58e-06	0.000103	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.56e-06	0.000102	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	3.56e-06	0.000102	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	3.55e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.54e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.53e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.52e-06	0.000101	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	3.5e-06	0.000101	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.43e-06	9.87e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	3.4e-06	9.77e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.36e-06	9.65e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	3.31e-06	9.5e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.28e-06	9.42e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.28e-06	9.42e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	3.25e-06	9.33e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.21e-06	9.22e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.21e-06	9.22e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	3.18e-06	9.13e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	3.17e-06	9.1e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.09e-06	8.87e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	3.08e-06	8.86e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	3.04e-06	8.75e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.02e-06	8.67e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.92e-06	8.4e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.87e-06	8.24e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.81e-06	8.07e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.78e-06	8e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.78e-06	7.98e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.76e-06	7.95e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.75e-06	7.91e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.75e-06	7.9e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.73e-06	7.85e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.72e-06	7.82e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.72e-06	7.82e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.7e-06	7.77e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.69e-06	7.73e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.63e-06	7.56e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.6e-06	7.48e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.57e-06	7.39e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.55e-06	7.33e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.55e-06	7.32e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.54e-06	7.3e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.5e-06	7.17e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.42e-06	6.97e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.37e-06	6.82e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	2.37e-06	6.81e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.36e-06	6.79e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—INS—type 2 diabetes mellitus	2.32e-06	6.68e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.31e-06	6.64e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.17e-06	6.23e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	2.13e-06	6.12e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.13e-06	6.11e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.12e-06	6.09e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.08e-06	5.97e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	2.04e-06	5.86e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.04e-06	5.86e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.86e-06	5.36e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.63e-06	4.69e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.6e-06	4.59e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.51e-06	4.33e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.47e-06	4.24e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	9.37e-07	2.69e-05	CbGpPWpGaD
